

1           ***Legionella pneumophila* modulates host cytoskeleton by an effector of**  
2           **transglutaminase activity**

3

4           Yan Liu, Yao Liu<sup>a</sup>, Zhao-Qing Luo<sup>\*</sup>

5

6           Purdue Institute for Inflammation, Immunology and Infectious Diseases and Department  
7           of Biological Sciences, Purdue University, West Lafayette, IN, United States of America

8           \*,Correspondence: luoz@purdue.edu

9

10          <sup>a</sup> Current address: PTC Therapeutics, 100 Corporate Ct #2400, South Plainfield, NJ  
11          07080

12

13 **Abstract**

14 The bacterial pathogen *Legionella pneumophila* delivers more than 330 effector proteins  
15 into host cells through its Dot/Icm type IV secretion system (T4SS) to facilitate its  
16 intracellular replication. A number of these effectors modulate organelle trafficking  
17 pathways to create a membrane-bound niche called the *Legionella* containing vacuole  
18 (LCV). In this study, we found that *L. pneumophila* induces F-actin accumulation in host  
19 cell cortex by its Dot/Icm substrate RavJ (Lpg0944). RavJ harbors an C<sub>101</sub>H<sub>138</sub>D<sub>170</sub> motif  
20 associated with human tissue transglutaminases (TGs). We showed that RavJ catalyzes  
21 a covalent linkage between actin and the Motin family proteins Angiomotin (AMOT) and  
22 Angiomotin-like 1 (AMOTL1), proteins known to regulate tube formation and cell  
23 migration. Further study revealed that RavJ-induced crosslink between actin and AMOT  
24 occurs on its Gln<sub>354</sub> residue. Crosslink between actin and AMOT significantly reduces the  
25 binding between actin and its binding partner cofilin, suggesting that RavJ inhibits actin  
26 depolymerization. We also demonstrated that the metaeffector LegL1 directly interacts  
27 with RavJ to antagonize its transglutaminase activity, leading to reduced crosslink  
28 between actin and Motin proteins. Our results reveal a novel mechanism of modulating  
29 the host actin cytoskeleton by *L. pneumophila*.

30

31 **Introduction**

32 *Legionella pneumophila* is a Gram-negative intracellular pathogen that causes  
33 Legionnaires' disease in humans[1]. Successful colonization by this bacteria requires its  
34 ability to manipulate such diverse processes of host cells as membrane trafficking,  
35 immunity, protein translation, autophagy, gene expression, and cytoskeleton structure[2,  
36 3]. Upon entry into host cells, *L. pneumophila* promotes the biogenesis of a phagosome  
37 structure called the *Legionella*-containing vacuole (LCV) that supports its intracellular  
38 replication[4]. The virulence of *L. pneumophila* is correlated with its ability to survive and  
39 replicate in the LCV[4]. Biogenesis of the LCV requires the Dot/Icm system that transports  
40 over 330 protein substrates into the host cell[5, 6]. The activity of these effectors is  
41 essential for the development and maintenance of this replicative niche[4].

42 The actin cytoskeleton is involved in many essential cellular events such as  
43 mitosis, cell migration, control of epithelial barrier function, and adherence of immune  
44 cells[7]. Given the essential roles of the actin cytoskeleton, it is not surprising that this  
45 network is a common target for bacterial virulence factors[8]. *Yersinia* blocks macrophage  
46 phagocytosis by interfering with host Rho GTPase and the actin cytoskeleton  
47 dynamics[9]. *Salmonella enterica* Typhimurium delivers a subset of bacterial effector  
48 proteins into the eukaryotic host cell to modulate the host cell actin cytoskeleton,  
49 facilitating its own internalization into non-phagocytic cells[10]. *L. pneumophila* has also  
50 acquired the ability to modulate the actin cytoskeleton by its Dot/Icm substrates. For  
51 example, RavK is a protease that disrupts host cytoskeletal structure by cleaving  
52 actin[11]; LegK2 targets the actin nucleator ARP2/3 complex by phosphorylating its  
53 components ARPC1B and ARP3, leading to the global actin cytoskeleton remodeling in

54 cells[12]; Ceg14 affects actin distribution and inhibits actin polymerization by a yet  
55 unknown mechanism[13]; VipA interferes with organelle trafficking by acting as a  
56 nucleator for actin polymerization[14].

57 Post-translational modifications (PTMs) of host proteins involved in important  
58 cellular processes is a commonly used mechanism used by bacterial pathogens to  
59 counteract host defense[15]. PTMs often is executed by virulence factors that display  
60 diverse biochemical activities. A number of unique PTMs have been found to be imposed  
61 by Dot/Icm effectors, including phosphorylcholination[16, 17], AMPylation[18],  
62 phosphorylation[19], ADP-ribosylation[20-22], ubiquitination[20, 23], and  
63 transglutamination[23]. Among these, transglutamination is induced by  
64 transglutaminases (TGs) that primarily catalyze the formation of an isopeptide bond  
65 between the  $\gamma$ -carboxamide group of a glutamine residue from one protein and the  $\epsilon$ -  
66 amino group of a lysine residue of another protein with the release of an ammonia[24].  
67 This modification has been identified as an important PTM that attacks a wide spectrum  
68 of host functions to benefit the pathogens. For example, the HopX (AvrPphE) family of  
69 *Pseudomonas syringae* Type III effectors are composed of a conserved putative cysteine-  
70 base catalytic triad resemble of the transglutaminase family that is required for the  
71 generation of a cell-death response in specific *Arabidopsis* ecotypes[25]. The type III  
72 effector VopC promotes *Vibrio* invasion by activating Rac and CDC42 via its  
73 transglutaminase activity[26]. Modification by transglutamination by *L. pneumophila*  
74 effectors has recently emerged as an important virulence factor of this bacterium. The *L.*  
75 *pneumophila* effector MavC has been characterized as a transglutaminase that catalyzes


76 the formation of a covalent linkage between ubiquitin and UBE2N, leading to the inhibition  
77 of NF- $\kappa$ B signaling in the initial phase of bacterial infection[23].

78 Here, we showed that the Dot/Icm substrate RavJ (Lpg0944) catalyzes crosslink  
79 between actin and members of the Motin family, AMOT and AMOTL1, via its  
80 transglutaminase activity, leading to accumulation of actin polymers in mammalian cells.  
81 We also showed that the transglutaminase activity of RavJ is regulated by another  
82 Dot/Icm substrate LegL1(Lpg0945), which directly binds to RavJ and inhibits the  
83 enzymatic activity of RavJ.

84 **Results**

85 **RavJ is a transglutaminase that induces actin accumulation in mammalian cells.**  
86 RavJ was originally identified in a study aiming to analyze the mechanism of metaeffector  
87 activity in *L. pneumophila*[27]. Structural analysis reveals that RavJ harbors a C-H-D  
88 (C<sub>101</sub>H<sub>138</sub>D<sub>170</sub>) motif associated with members of tissue transglutaminases (TGs)[27]. In a  
89 screening to identify Dot/Icm substrates capable of regulating the actin cytoskeleton, we  
90 transfected HEK293T cells with a GFP fusion library of Dot/Icm substrates and found that  
91 RavJ causes rearrangements of the actin cytoskeleton in mammalian cells (**Fig 1**). To  
92 determine the role of the putative catalytic motif potentially involved in TG activity in the  
93 function of RavJ, we introduced mutations in C<sub>101</sub>, H<sub>138</sub>, D<sub>170</sub>, respectively, and found that  
94 each of these mutations completely abolished the ability of RavJ to induce actin  
95 cytoskeleton rearrangements (**Fig 1**). These results indicate that overexpression of RavJ  
96 triggers the formation of actin filaments in the cell cortex by a mechanism that requires its  
97 C<sub>101</sub>H<sub>138</sub>D<sub>170</sub> motif.

98



99


**Fig 1. Ectopic expression of RavJ causes rearrangement of actin cytoskeleton.**

HEK293T cells were transfected with the indicated constructs and then subjected to immunofluorescence microscopic analysis. F-actin was stained by phalloidin conjugated with Texas-Red. Bar, 10  $\mu$ m. Note that wild-type RavJ induces actin accumulation in the cell cortex and this phenotype is dependent on the predicted TG enzymatic motif.

100 ***ravJ* is dispensable for intracellular growth of *L. pneumophila***

101 To examine the role of *ravJ* in *L. pneumophila* virulence, we first determined the level of  
102 RavJ at different growth phases throughout its growth cycle in broth. RavJ was detectable  
103 in all growth phases (optical density at 600 nm (OD<sub>600</sub>) of 0.5-3.5) but became highly  
104 expressed in the lag phase (OD<sub>600</sub>=0.5-0.7) (**Fig 2A**) after saturated cultures were diluted  
105 into fresh medium, suggesting that RavJ functions in the initial phase of infection.


106 We also determined the role of *ravJ* in *L. pneumophila* virulence by examining  
107 intracellular bacterial replication of relevant bacterial strains. The mutant Lp02Δ*ravJ* grew  
108 at rates indistinguishable from that of the wild-type strain (**Fig 2B-C**), indicating that,  
109 similar to most Dot/Icm substrates, RavJ is not required for proficient intracellular bacterial  
110 replication in commonly used tissue culture hosts.



111

**Fig 2. *ravJ* does not influence intracellular growth of *L. pneumophila*.** **A.** The growth of *L. pneumophila* in AYE broth (right) and the expression of RavJ in bacteria grown in broth (left). Cultures grown to stationary phase were diluted 1:20 into fresh medium and the growth of bacteria was monitored by measuring OD<sub>600</sub> at the indicated time points. **B-C.** The  $\Delta$ ravJ strain grew at rates indistinguishable from that of the wild-type strain in commonly used tissue culture hosts. Bone marrow-derived mouse macrophages (BMDMs) (**B**) or *Dictyostelium discoideum* (**C**) were infected with relevant *L. pneumophila* strains at the indicated time points, cells were treated with 0.02% saponin for half an hour and the bacteria number was determined by enumerating colony-forming unit (CFU) of appropriately diluted lysates obtained by saponin. Errors bars represent  $\pm$ SEM; n=3;


112 **Ectopically expressed RavJ crosslinks with actin.** TGs function to catalyze homo- or  
113 heterologous protein crosslink by a transglutamination reaction[24]. The key to  
114 understand the mechanism of how RavJ induces actin rearrangement is to identify its  
115 target proteins. To achieve this goal, we expressed Flag-tagged RavJ or the RavJ<sub>C101A</sub>,  
116 RavJ<sub>H138A</sub>, RavJ<sub>D170A</sub> mutants in HEK293T cells. Cell lysates were subjected to  
117 immunoprecipitation with beads coated with the Flag antibody. Detection of the  
118 precipitated proteins by immunoblotting with the Flag antibody revealed that a portion of  
119 wild-type RavJ but not the mutants migrated as higher molecular weight (MW) forms (**Fig**  
120 **3A**), suggesting it is posttranslationally modified. To identify the modification associated  
121 with the upshifted protein, we expressed double-tagged Flag-RavJ-His<sub>6</sub> in HEK293T cells  
122 and used a two-step sequential purification procedure to obtain upshifted RavJ (**Fig 3B**).  
123 Mass spectrometric analysis of proteins in the upshifted band identified abundant actin  
124 and RavJ, suggesting that the upshifted band is a product generated by protein  
125 conjugation between these two proteins.




**Fig 3. RavJ induces a molecular weight shift in actin by a putative transglutaminase activity. A.** A portion of RavJ migrated as a higher molecular weight form when expressed in mammalian cells. HEK293T cells were transfected to express Flag-RavJ, RavJ<sub>C101A</sub>, RavJ<sub>H138A</sub>, or the RavJ<sub>D170A</sub> mutants. Total cell lysates were immunoprecipitated (IP) with beads coated with the Flag antibody. Products were resolved by SDS-PAGE and probed with the Flag antibody. Note that RavJ displayed as an upshifted band on the blot. **B.** Tandem purification of the Flag-RavJ-His<sub>6</sub> upshifted band. HEK293T cells were transfected to express Flag-RavJ-His<sub>6</sub>. Cell lysates were subjected to IP with beads coated with the Flag antibody. Proteins were then eluted from the beads with 3xFLAG peptide and incubated with Ni<sup>2+</sup>-NTA beads. Products were separated by SDS-PAGE and detected by silver staining. **C.** RavJ forms a covalent bond with actin in mammalian cells. HEK293T cells expressing the indicated proteins were subjected to IP with beads coated with the Flag antibody and separated by SDS-PAGE. Samples were detected by Flag-specific (left) and RavJ-specific (right) antibody, respectively.

127

128



**Fig 4. Actin is crosslinked to RavJ through its Gln354 residue. A.** MS analysis of the Flag-RavJ-His<sub>6</sub> upshifted band. Coverage of the amino acids in actin are highlighted in blue. Note that Lys<sub>84</sub>, Lys<sub>118</sub>, Lys<sub>213</sub>, Lys<sub>359</sub>, Gln<sub>121</sub>, Gln<sub>137</sub>, Gln<sub>353</sub>, Gln<sub>354</sub> were not recovered from the MS, indicating them as potential linkage residues. **B.** The formation of Actin-RavJ was detected by immunoblotting. Note that the Actin Gln354Ala mutant has largely lost the ability to be modified (the 3<sup>rd</sup> lane).



**S1 Fig. Determination of the crosslink site in actin. A-B.** HEK293T cells co-transfected to express the indicated proteins were lysed and immunoprecipitated by beads coated with the Flag-specific antibody. Note that only the Gln354Ala mutation in actin abolished the crosslink products induced by RavJ.


129

130 To test whether the upshifted band is a crosslink product between actin and RavJ,  
 131 we coexpressed Flag-tagged actin and GFP fusion of RavJ or its mutants in HEK293T  
 132 cells. Cell lysates were subjected to immunoprecipitation using agarose beads coated  
 133 with the Flag-specific antibody. We found that GFP-RavJ indeed was linked with actin  
 134 (**Fig 3C**). To identify the chemical linkage between actin and RavJ, the protein band  
 135 corresponding to the RavJ upshifted band was excised, digested with trypsin, and  
 136 analyzed by mass spectrometry (MS). TGs catalyze protein crosslinking by forming an  
 137 isopeptide bridge between the lysine (Lys) donor residue of one protein and the acceptor  
 138 glutamine (Gln) residue of another[24]. Thus, we hypothesized that a lysine residue and

139 a glutamine residue are involved in the crosslink between RavJ and actin. In the MS  
140 analysis, around 80% of the peptides in actin were recovered from the tryptic digestion,  
141 indicating Lys<sub>84</sub>, Lys<sub>118</sub>, Lys<sub>213</sub>, Lys<sub>359</sub>, Gln<sub>121</sub>, Gln<sub>137</sub>, Gln<sub>353</sub>, Gln<sub>354</sub> in actin as potential  
142 lysine donor residues or glutamine acceptor residues (**Fig 4A**). Among the individual  
143 mutation of these residues, only Q354A in actin abolished the ability of actin to crosslink  
144 with RavJ (**Figs 4B and S1A-B**).

145 **RavJ induces crosslink between actin and members of the Motin family protein.**  
146 Transglutaminases normally catalyze crosslink between two proteins, and in the absence  
147 of the receptor substrate, these enzymes induce crosslink between itself and the available  
148 donor substrate. Our analysis of the precipitated products obtained by RavJ identified a  
149 number of proteins (**Fig 3C**), one or more of which could be potentially the second  
150 substrate that crosslinks with actin in the reaction induced by RavJ. To identify such  
151 proteins, we purified the crosslink products using a tandem purification method from cells  
152 transfected to express Flag-HA-actin and GFP-RavJ. Samples similarly transfected to  
153 express the catalytically inactive RavJ<sub>C101A</sub> mutant were used as controls. Twenty-four  
154 hours after transfection, cell lysates were subjected to IP with beads coated with the Flag  
155 antibody. Proteins eluted with 3XFLAG peptide were further purified by IP with the HA  
156 antibody. Samples separated by SDS-PAGE were detected by immunoblotting with the  
157 appropriate antibodies. In samples transfected to express GFP-RavJ, several upshifted  
158 bands were detected with the anti-Flag antibody (**S2A Fig**). The gels containing upshifted  
159 proteins were excised, digested with trypsin, and analyzed by mass spectrometry, which  
160 allowed us to obtain a list of proteins that potentially crosslink with actin (**Table 1**). Two  
161 of Wiskott-Aldrich syndrome and SCAR homolog (WASH) complex components,

162 WASHC4 and WASHC5, and one protein from the Motin family, Angiomotin (AMOT) were  
163 among the proteins identified with high confidence. We considered these proteins as  
164 potential substrates of RavJ because of their relevance to the actin cytoskeleton network.  
165 Further analysis showed that RavJ did not detectably induce crosslink between actin and  
166 WASHC4 or WASHC5 (**S2B-2C Fig**). Importantly, we found that AMOT is able to form a  
167 conjugate with actin when coexpressed with RavJ (**Fig 5B**), suggesting that AMOT is the  
168 second substrate of the crosslinking reaction catalyzed by RavJ.



**S2 Fig. Identification of the cellular targets of RavJ.** **A.** Tandem purification of actin crosslink products catalyzed by RavJ. HEK293T cells co-transfected to express Flag-HA-Actin, GFP-RavJ or GFP-RavJ<sub>C101A</sub> were subjected to IP with beads coated with the Flag antibody. Proteins were eluted from the beads by 3XFLAG peptide. Elution fractions were then immunoprecipitated with beads coated with the HA-specific antibody. Products resolved by SDS-PAGE were detected by silver staining (right) or probed with the Flag antibody(left). Gel plug corresponding to the upshifted band was cut for MS analysis. **B-C.** WASHC4 and WASHC5 do not crosslink with actin in the presence of RavJ. HEK293T cells co-transfected to express the indicated proteins were lysed and immunoprecipitated by beads coated with the Flag-specific or HA-specific antibody. Note that there is no crosslink products detected between actin and WASHC4 or WASHC5.


170

**Table 1: Top hits from MS analysis of the tandem purification**

Protein Names	Ratio (RavJ/RavJ <sub>C101A</sub> )	MS/MS count RavJ <sub>C101A</sub>	MS/MS count RavJ	Mol. weight [kDa]
Actin	29.68	25	742	42
Splicing factor, proline- and glutamine-rich	19.5	2	39	76
Kinesin-like protein KIF11	17.5	6	105	119
Adenylyl cyclase-associated protein 1	7.78	14	109	51
Cytoplasmic dynein 1 heavy chain 1	∞	0	155	532
Eukaryotic translation initiation factor 4 gamma 1	∞	0	84	158
Filamin-A	∞	0	63	280
WASH complex subunit strumpellin (WASHC5)	∞	0	52	134.28
Talin-1	∞	0	44	270
Insulin receptor substrate 4	∞	0	42	133
WASH complex subunit 7 (WASHC4)	∞	0	35	136.4
Afadin	∞	0	22	210
Eukaryotic translation initiation factor 4 gamma 2	∞	0	19	98
General transcription factor II-I	∞	0	18	108
Vigilin	∞	0	17	141
Src substrate cortactin	∞	0	16	57
Angiomotin	∞	0	5	130

171


172 To verify that AMOT is targeted by RavJ, we tested the crosslink between  
173 endogenous actin and AMOT. In cells transfected to express GFP-RavJ, crosslink  
174 products formed by endogenous actin and AMOT were detected (**Fig 5C**). We also  
175 observed crosslink between actin and AMOT-p80 (**Fig 5D**), an AMOT isoform arose from  
176 alternative splicing of the *AMOT* transcript (**Fig 5A**). In addition, we have tested  
177 Angiomotin-like 1 (AMOTL1), which is another member in the Motin family having  
178 significant homology with AMOT. Crosslink products of AMOTL1 and actin were detected  
179 in HEK293T cells expressing wild-type RavJ but not its catalytically inactive mutants (**Fig**  
180 **5E**). Taken together, our results indicate that RavJ catalyzes the crosslink between actin  
181 and members of the Motin family.



**Fig 5. RavJ catalyzes crosslinks between actin and members of the Motin protein family.** **A.** A schematic view of the two isoforms of AMOT produced by alternative splicing of the *AMOT* mRNA. The two isoforms, AMOT-p130 and AMOT-p80, are characterized by a conserved coiled-coil domain, a C-terminal PDZ binding domain, and an angiostatin binding domain. The AMOT-p130 isoform harbors a unique N-terminal domain. **B.** Actin conjugates with AMOT-p130 in the presence of RavJ. HEK293T cells co-transfected with the indicated proteins were lysed and subjected to IP with beads coated with the Flag antibody or the HA antibody. Samples resolved by SDS-PAGE were probed with a Flag-specific antibody or an HA-specific antibody. **C.** RavJ induces crosslink between HA-AMOT and endogenous actin. Cells expressing HA-AMOT-p130 and GFP-RavJ or the GFP-RavJ<sub>C101A</sub> mutant were lysed and immunoprecipitated with beads coated with the HA antibody. Crosslink products were probed by immunoblotting using either Actin or Flag antibody.


**D.** Actin forms a conjugate with AMOT-p80 in HEK293T cells in the presence of RavJ. Cells transfected to express the indicated proteins were lysed and subjected to IP with beads coated with Flag or HA antibody, followed by immunoblotting analysis. The proteins were detected by antibodies specific to a Flag, RavJ or HA. **E.** RavJ catalyzes the crosslink between AMOTL1 and actin. Cells transfected to express the indicated proteins were lysed and subjected to reciprocal IP, followed by SDS-PAGE analysis, and was probed with the indicated antibodies.

183 The Motin family of proteins harbor several structural domains, including the N-  
184 terminus domain potentially involved in Yes-associated protein 1 (YAP1) binding[28], a  
185 conserved coiled-coil (CC) domain and the C-terminal PDZ-binding domain[29] (**Fig 6A**).  
186 To determine the crosslink site on AMOT, we constructed a number of HA-tagged AMOT  
187 truncation mutants (**Fig 6A**) and tested their ability to crosslink with actin in cells  
188 expressing RavJ. Our results showed that all the four truncations were able to crosslink  
189 with actin (**Fig 6B-C and 6F**). To identify the modification sites on each truncation, the  
190 corresponding crosslink products were subjected to MS analysis (**S3A-C Fig**). However,  
191 despite multiple attempts using different enzymes to digest the crosslink products, we  
192 were unable to detect the crosslink sites between the two proteins. The mass of the  
193 peptide without the crosslink is too big to extract the peptide from the gel and to sequence  
194 it. We then mutated the two lysine residues in the truncation contains the PDZ-binding  
195 domain (**Fig 6E**). Substitution mutant in Lys<sub>1051</sub> was enough to abolish the crosslink  
196 product (**Fig 6E**). The same mutation in the AMOT<sub>871-1084</sub> truncation also abolished the  
197 crosslink product (**Fig 6D**), suggesting that AMOT<sub>871-1084</sub> crosslinks with actin through its  
198 Lys<sub>1051</sub> residue.



199

**Fig 6. Determination of the modification sites on AMOT.** HEK293T cells were transfected to express the indicated proteins. Cell lysates were subjected to reciprocal co-IP with Flag or HA antibody coated beads. Crosslink products were detected by immunoblotting with the indicated antibodies. **A.** Domain architecture of the Motin family of proteins and the AMOT-p130 truncations. The HA-tagged truncation mutants are made as indicated. **B.** The PDZ binding domain is enough to crosslink with actin. **C.** The AMOT coiled-coil truncation (AMOT<sub>410-870</sub>) crosslinks with actin in the presence of RavJ. **D.** The Lys<sub>1051</sub>Ala mutation in the AMOT<sub>871-1084</sub> truncation abolished its ability to crosslink with actin. **E.** The Lys<sub>1051</sub>Ala mutation in the PDZ binding domain lost its ability to crosslink with actin. **F.** RavJ catalyzes the formation of a covalent bond between the N-terminal domain of AMOT-p130 and actin.



**S3 Fig. Determination of the crosslink sites in AMOT. A-C.** Tandem purification of crosslink products of actin and AMOT truncations. HEK293T cells co-transfected to express the indicated proteins were subjected to IP with beads coated with the Flag antibody. Proteins were eluted from the beads by 3XFLAG peptide. Elution fractions were then immunoprecipitated with beads coated with the HA-specific antibody. Products resolved by SDS-PAGE were detected by silver staining (right) or probed with the indicated antibodies(left). Protein bands corresponding to the crosslink products were excised for MS analysis.

200

201 **RavJ catalyzes crosslink between purified actin and AMOT.** We next examined  
202 whether crosslink between actin and AMOT occurs in cell-free reactions. HEK293T cells


203 transfected to express Flag-Actin, HA-AMOT, GFP-RavJ or GFP-RavJ<sub>C101A</sub>, respectively,  
204 were lysed, and the lysates were mixed and incubated at 37°C for 2 h. Beads coated with  
205 the Flag antibody were used to enrich Flag-Actin and products of crosslinking formed by  
206 actin and AMOT were detected by immunoblotting. Protein conjugate detectable by the  
207 HA-specific antibody was detected only in reactions that received lysates containing wild-  
208 type RavJ (**Fig 7A**), indicating that RavJ-induced crosslink between actin and AMOT  
209 occurs in a cell-free system.

210 To further determine the activity of this transglutaminase, recombinant RavJ  
211 purified from *E. coli* was incubated with Flag-Actin and HA-AMOT purified from HEK293T  
212 cells, and the production of a crosslink product was detected after the reactions were  
213 allowed to proceed for 2 h at 37°C (**Fig 7B**). Consistent with results from earlier  
214 experiments with cell lysates, adding His<sub>6</sub>-RavJ<sub>C101A</sub> to the reactions did not cause  
215 crosslink between these two proteins (**Fig 7B**). Together, these results establish that  
216 RavJ is a transglutaminase that catalyzes crosslink between AMOT and actin.


217 ***L. pneumophila* induces crosslinking between actin and AMOT in a RavJ-  
218 dependent manner.** Our results from ectopic expression by transfection strongly suggest  
219 that RavJ catalyzes protein crosslink between AMOT and actin. To determine whether  
220 this reaction is physiologically relevant, we attempted to determine the activity of RavJ  
221 during *L. pneumophila* infection. HEK293T cells transfected to express the Fc<sub>YII</sub> receptor  
222 were infected with opsonized bacteria of relevant *L. pneumophila* strains at an multiplicity  
223 of infection (MOI) of 50. No crosslink between AMOT and actin was detected in cells  
224 infected with strain Lp03, an avirulent *dotA* mutant, or the wild-type stain Lp02 (**S4 Fig**).  
225 Considering the possibility that the amount of crosslinked products was too low in

226 samples infected with strain Lp02, we examined whether overexpression of RavJ in the  
227 wild-type strain background allows us to detect the crosslink products. Indeed, infection  
228 of the cells with strain  $\Delta$ ravJ(pRavJ) led to robust crosslink between AMOT and actin (Fig  
229 7C). In contrast, crosslink did not occur in cells similarly infected with strain  
230  $\Delta$ ravJ(pRavJ<sub>C101A</sub>), which overexpressed the enzymatically inactive RavJ mutant (Fig  
231 7C). These results indicate RavJ catalyzes crosslink between actin and AMOT in cells  
232 infected with *L. pneumophila* competent in the Dot/Icm system that overexpressed wild-  
233 type RavJ. The amount of crosslink products in cells infected with the wild-type strain  
234 likely was not sufficient for detection with our method, RavJ likely catalyzes the crosslink  
235 between actin and the Motin family of proteins.

236



**S4 Fig. Determination of the effect of RavJ during bacterial infection.** HEK293T cells transfected to express the Fc $\gamma$ II receptor were treated with opsonized bacterial strains as indicated. Cells were collected at 4 h after infection and were lysed by 0.2% saponin. RavJ and SidC translocation were detected by RavJ-specific or SidC-specific antibodies. Tubulin was probed as a loading control.




237

**Fig 7. RavJ induces the formation of a protein conjugate by actin and AMOT** **A.** RavJ catalyzes crosslink between actin and AMOT in a cell-free system. Cells transfected to express Flag-Actin, HA-AMOT, GFP-RavJ, or GFP-RavJ<sub>C101A</sub>, respectively, were lysed with RIPA buffer without EDTA. Cell lysates were combined as indicated and incubated at 37°C for 2 h. Products were subjected to IP with beads coated with the Flag antibody, followed by immunoblotting with the indicated antibodies. **B.** RavJ induces crosslink between purified actin and AMOT *in vitro*. Reactions containing Flag-Actin, HA-AMOT, His<sub>6</sub>-RavJ or His<sub>6</sub>-RavJ<sub>C101A</sub> were incubated at 37°C for 2 h. Samples were immunoprecipitated with beads coated with the Flag antibody. The crosslink products were detected by the indicated antibodies. **C.** Crosslink between endogenous actin and AMOT was detected in cells infected with *L. pneumophila* overexpressing RavJ. HEK293T cells transfected to express the FcγII receptor were infected with the indicated bacterial strains for 4 h at an MOI of 50. Cells were lysed with 0.2% saponin and then resolved by SDS-PAGE. The blots were probed with the indicated antibodies.

238 **Simultaneous knockdown of AMOT and AMOTL1 interferes with the formation of**  
239 **actin filaments induced by RavJ.** Ectopic expression of RavJ in mammalian cells led to  
240 the formation of actin filaments (**Fig 1**). The observation that RavJ induces protein  
241 crosslink between AMOT and actin suggests that this event is important for the actin  
242 polymerization phenotype. To examine the relevance between protein crosslink and the  
243 formation of actin filaments, we determined the impact of AMOT depletion on RavJ-  
244 induced actin filament formation. To this end, we introduced shRNAs that target mRNAs  
245 of both AMOT and AMOTL1 into HEK293T cells, which is known to express high levels  
246 of these two isoforms but almost an undetectable level of AMOTL2[30]. Introduction of  
247 shRNAs by lentiviral transduction led to significant reduction of the protein levels of both  
248 AMOT and AMOTL1 (**Fig 8A**). Next, we expressed RavJ in these cells by transfection  
249 and examined the formation of actin filaments by phalloidin staining. In samples that  
250 received scramble shRNAs, actin filaments were readily detected at rates similar to  
251 untreated cells (**Fig 8B**). Consistently, crosslink between actin and AMOT became  
252 undetectable in these cells (**Fig 8C**). Furthermore, overexpression of AMOT by  
253 transfection rescued not only RavJ-induced formation of actin filaments but also the  
254 crosslink between actin and AMOT (**Fig 8B-C**). Taken together, these results support a  
255 conclusion that members of the Motin family of proteins are important for RavJ-induced  
256 actin accumulation by forming protein conjugates with actin.

257




**Fig 8. Knockdown of AMOT and AMOTL1 reduced actin accumulation in HEK293T cells induced by RavJ.**

**A.** Expression level of AMOT and AMOTL1 was examined by Western blot. The expression of the proteins was probed in cell lysates of two clones of AMOT knockdown cells and two clones of AMOT and AMOTL1 double knockdown cells. Proteins were detected by an AMOT-p130-specific antibody and an AMOTL1-specific antibody. Tubulin was detected as a loading control. **B.** AMOT and AMOTL1 double knockdown in HEK293T cells significantly reduced actin accumulation in cells expressing wild-type RavJ. Cells transfected to express the indicated proteins were fixed and stained with phalloidin conjugated with Texas-red. Bar, 10  $\mu$ m. Phalloidin fluorescence signal was quantified by Image J software to evaluate the amount of F-actin (the left panel). Data are the mean SEM (\*\*p<0.001). **C.** Knockdown of AMOT and AMOTL1 in HEK293T cells abolished crosslink between actin and the Motin family of protein. Cells were transfected to express the indicated proteins and samples were subjected to IP with beads coated with the Flag antibody. Crosslinking products were detected with the Flag-specific antibody and AMOT-specific antibodies, respectively.

**D. RavJ inhibits the binding between actin and cofilin. Cells transfected to express the indicated proteins were lysed and subjected to IP with beads coated with the Flag-specific antibody. Binding between actin and cofilin were detected by the indicated antibodies.**

259

260 **RavJ interferes with the interaction between actin and cofilin.** Earlier studies suggest  
261 that actin interacts with profilin and cofilin through its Gln<sub>354</sub> residue[31-33]. Cofilin  
262 depolymerizes and severs actin filaments while profilin binds to actin monomers and  
263 provides ATP-Actin for incorporation into actin filaments[34]. The fact that actin crosslinks  
264 with RavJ and AMOT via Gln<sub>354</sub> inspired us to investigate whether RavJ affects the  
265 binding between actin and actin binding proteins. HA-profilin-1, HA-profilin-2 or GFP-  
266 cofilin were expressed in HEK293T cells along with relevant proteins, and cell lysates  
267 were subjected to immunoprecipitation with the Flag-specific antibody. Interestingly,  
268 expression of RavJ reduced the binding between actin and cofilin (**Figure 8D**), but not  
269 profilin-1 and profilin-2 (**S5A-B Fig**), suggesting that RavJ-induced actin accumulation in  
270 cell cortex was a result of reduced actin depolymerization.



271


**S5 Fig. Effects of RavJ on the binding between actin and actin binding proteins. A-B.**

RavJ does not influence the binding between actin and actin binding proteins, profilin 1 and profilin 2. HEK293T cells co-transfected to express the indicated proteins were lysed and subjected to IP with beads coated with a Flag-specific antibody.


272 **LegL1 blocks the activity of RavJ by sterically hindering its catalytic site.** In a  
273 previous study, LegL1 (Lpg0945) was identified as a putative metaeffecter of RavJ which  
274 interacts with its amino terminus containing the predicted motif important for its enzymatic  
275 activity[27]. We then tested whether LegL1 can influence actin cytoskeleton  
276 rearrangement induced by RavJ. Coexpression of HA-LegL1 with GFP-RavJ significantly  
277 reduced the formation of crosslink products by actin and AMOTs and such reduction  
278 became more apparent as the ratio between LegL1 and RavJ increased (**Fig 9A**),  
279 indicating that LegL1 inhibits the activity of RavJ. The inhibitory effect of LegL1 can  
280 attribute to at least two potential mechanisms: LegL1 reverses the crosslink by an  
281 enzymatic activity, or it inhibits the activity of RavJ by direct binding.

282 To distinguish between these two possibilities, we pre-incubated cell lysates  
283 expressing HA-LegL1 with cell lysates expressing GFP-RavJ for 1 h at 37°C. Cell lysates  
284 expressing HA-AMOT and Flag-Actin, respectively, were then added to the cell-free  
285 system. RavJ that has been pre-incubated with HA-LegL1 was unable to induce crosslink  
286 between actin and AMOT, suggesting that LegL1 blocks the activity of RavJ (**Fig 9B**).  
287 Furthermore, addition of HA-LegL1 to reactions containing crosslinked actin-AMOT did  
288 not detectably reduce the amount of the conjugate product (**S6 Fig**). We also tested the  
289 activity of recombinant LegL1 purified from *E. coli*. Incubation of GST-LegL1 with cell  
290 lysates expressing GFP-RavJ ablated its ability to catalyze crosslink between actin and  
291 AMOT (**Fig 9D**).

292 We next examined the interactions between LegL1 and RavJ in *L. pneumophila*.  
293 RavJ can be immunoprecipitated from lysates of *L. pneumophila* expressing Flag-LegL1  
294 with beads coated with the Flag antibody, indicating binding between LegL1 and RavJ  
295 (**Fig 9E**). We further tested the effect of LegL1 on RavJ-induced crosslink during bacterial  
296 infection. HEK293T cells were infected with *ravJ* mutant complemented with RavJ, the  
297 RavJ<sub>C101A</sub> mutant, or both RavJ and LegL1, at an MOI of 50. Crosslink between AMOT  
298 and actin was only detected in cells infected with the  $\Delta r\text{avJ}(\text{pRavJ})$  strain but not strain  
299  $\Delta r\text{avJ}(\text{pRavJ, pLegL1})$  (**Fig 9C**), suggesting that LegL1 effectively inhibits the crosslink  
300 caused by RavJ during bacterial infection. The translocation of RavJ into host cells is not  
301 influenced by LegL1, indicating that the regulation of RavJ by LegL1 is likely occurs in the  
302 host cells (**Fig 9F**). Collectively, these results indicate that LegL1 blocks the activity of  
303 RavJ by direct binding.



**S6 Fig. LegL1 does not reverse the transglutaminase activity of RavJ.** HEK293T cells transfected to express the indicated proteins were lysed and subjected to IP with beads coated with the Flag-specific antibody. Note that expression of HA-LegL1 did not remove actin from the crosslink product.



**Fig 9. LegL1 antagonizes the catalytic activity of RavJ. A.** expression of LegL1 in HEK293T cells reduced crosslink products induced by RavJ. Lysates of cells transfected to express the indicated proteins were subjected to IP with beads coated with the Flag antibody and the products resolved by SDS-PAGE were detected with the indicated antibodies. **B.** LegL1 inhibits the activity of RavJ in a cell-free system. Cells transfected to express Flag-Actin, HA-LegL1, HA-AMOT, GFP-RavJ, and GFP-RavJ<sub>C101A</sub>, respectively, were lysed with RIPA buffer without EDTA. Lysates of HA-LegL1 was pre-incubated with those expressing GFP-RavJ for 1 h at 37°C. Reactions containing the indicated cell lysates were immunoprecipitated with beads coated with the Flag antibody and proteins were detected with the indicated antibodies. **C.** Overexpression of LegL1 in *L. pneumophila* inhibits the enzymatic activity of RavJ. Bacteria of the indicated *L. pneumophila* strains were opsonized prior to infecting HEK293T cells transfected to express the Fc $\gamma$ II receptor at an MOI of 50 for 4 h. Cells lysed with 0.2% saponin were probed with the indicated antibodies.

**D.** Recombinant LegL1 reduces the crosslink products induced by RavJ. Cells transfected to express Flag-Actin, HA-AMOT, GFP-RavJ, and GFP-RavJ<sub>C101A</sub>, respectively, were lysed with RIPA buffer without EDTA. 10 µg GST-LegL1 was pre-incubated with cell lysates of GFP-RavJ for 1 h at 37°C. Reactions containing the indicated components were immunoprecipitated with beads coated with the Flag antibody and proteins were detected with the indicated antibodies.

**E.** LegL1 directly binds to RavJ in *L. pneumophila*. Bacterial cells carrying either the vector pZLQ or pZLQ-LegL1 were lysed with RIPA buffer and then immunoprecipitated with beads coated with the Flag antibody. Binding between RavJ and LegL1 was detected by RavJ-specific antibodies and the Flag antibody, respectively **F.** Overexpression of LegL1 in *L. pneumophila* does not influence the translocation of RavJ. HEK293T cells transfected to express the Fc<sub>YII</sub> receptor were treated with different bacterial strains: 1. No infection, 2. Wild-type *L. pneumophila*. 3. Wild type *L. pneumophila* overexpressing Flag-LegL1. Cells were collected at the indicated time points and lysed by 0.2% saponin. RavJ and LegL1 translocation were detected by RavJ-specific antibodies and the Flag-specific antibody respectively. Tubulin was probed as a loading control.

306 **Discussion**


307         The actin cytoskeleton network is a major host structural component that provides  
308 structural and functional support in numerous vital cellular activities. It also directs the  
309 trafficking of cargo-containing vesicle trafficking throughout the cell by functioning as a  
310 highway[35]. Intracellular bacterial pathogens have evolved remarkable strategies to  
311 subvert the host cytoskeletal machinery to promote bacterial internalization, facilitate the  
312 biogenesis of bacteria-containing phagosomes, and co-opt actin-dependent movement  
313 to benefit pathogen dissemination[36]. To support diverse infection events, intracellular  
314 pathogens hijack the actin cytoskeleton by introducing effector proteins into the host  
315 cytosol by specialized secretion systems[8]. Among these, *Coxiella burnetii* triggers actin  
316 reorganization at the attachment site of phagocytic human macrophages by binding to  
317 CR3 receptors to stimulate bacterial internalization[37]. After entering a host cell, this  
318 bacterium replicates within an acidic compartment called the parasitophorous vacuole  
319 (PV) in macrophages. Optimal intracellular growth of *C. burnetii* requires F-actin  
320 accumulation around the PV, but the detailed mechanisms are not fully characterized[38].  
321 *Chlamydia* species replicate in a host membrane-derived compartment termed inclusion.  
322 Optimal development and maintenance of vacuole morphology and integrity require F-  
323 actin rings surrounding the inclusion to stabilize the organelle[39, 40]. Spotted Fever  
324 Group *Rickettsia*, such as *R. rickettsii* and *R. conorii*, escape the phagosome before  
325 lysosomal fusion after entering a host cell. After escape, these bacteria induce actin  
326 polymerization to form an actin tail that facilitates bacterial motility within the cell[41, 42].

327         Actin exists in two main forms of organization, the monomeric G-actin, and the  
328 filamentous form F-actin[43]. Polymerization and depolymerization of actin filaments are

329 kept in a dynamic balance to tightly regulate movement and other cell functions[43]. The  
330 VCA domains of N-WASP (Wiskott-Aldrich syndrome protein) and SCAR/WAVE  
331 (suppressor of Camp receptor/WASP-family verprolin homologous protein) activate the  
332 actin nucleator Arp2/3 complex to generate new F-actin branches from preexisting mother  
333 filaments[44]. Actin-depolymerizing factor ADF/cofilin regulates actin dynamics by  
334 depolymerizing filaments at their pointed ends, thereby restoring a pool of actin  
335 monomers for filament assembly[35]. Actin molecule harbors two main lobes separated  
336 by a deep upper cleft. Each main lobe is subdivided into two clearly discernible  
337 subdomains, SD1-4[45]. SD1, which is built from residues 1-32, 70-144, and 338-375,  
338 forms an important target area for a large number of actin-binding proteins such as profilin,  
339 cofilin and gelsolin[45]. Of note is that RavJ-induced actin crosslink with AMOT occurs at  
340 Gln354, a site locates on the SD1, suggesting that this crosslinking event may interfere  
341 with the interaction between actin subunits in the filament and the actin binding proteins.  
342 In agreement with this notion, the binding between cofilin and actin is significantly reduced  
343 (**Fig 8D**), indicating that RavJ functions to block actin depolymerization, resulting in the  
344 accumulation of F-actin in cell cortex.

345 It has been known for a long time that *L. pneumophila* avoids the delivery of its  
346 vacuole to lysosomes by modulating the ER-to-Golgi vesicle trafficking[46]. Shortly after  
347 being internalized by a host cell, the plasma membrane derived vacuole containing *L.*  
348 *pneumophila* will be converted into a compartment that has similarity to an ER-Golgi  
349 intermediate compartment[47-49]. The biogenesis of this specialized phagosome has  
350 been studied extensively[49]. A repertoire of Dot/Icm effectors have been demonstrated  
351 to hijack the host vesicle trafficking pathway directly[2, 50], some of them could affect this

352 cellular process indirectly to bypass the microbicidal endosomal compartment[51]. The  
353 modulation of the actin cytoskeleton clearly contributes to the development of the LCV.  
354 For example, the metal protease RavK cleaves actin, abolishing its ability to form actin  
355 polymers[11] whereas LegK2 phosphorylates components of actin nucleator ARP2/3  
356 complex and thus inhibits actin polymerization on the phagosome[11]. Ceg14 inhibits  
357 actin polymerization by a yet unknown mechanism[13]. These proteins are very likely  
358 working in synergic to temporally inhibit actin polymerization on the LCV and thus  
359 preventing fusion with late endosomes[12]. In contrast to the inhibitory effects of RavK  
360 and LegK2, VipA enhances actin polymerization by acting as an actin nucleator[14]. RavJ  
361 also appears to promote the formation of actin filaments. Here, we showed that RavJ-  
362 induced crosslink between actin and AMOT blocks the depolymerization activity of  
363 ADF/cofilin, resulting in the stabilization of actin polymers in cell cortex (**S7 Fig**). Clearly,  
364 in cells infected with *L. pneumophila*, its effectors strike a balance between the two states  
365 of actin. Balanced modulation of host processes has recently emerged as a prominent  
366 feature associated with the interactions between *L. pneumophila* and its hosts. In some  
367 cases, the balance is achieved by effector pairs with opposite biochemical activity which  
368 may function at different phases of infection[52]. In other cases, the importance of balance  
369 lies in the cellular locations of the molecular events regulated by the effectors[17]. In  
370 addition to other effectors that inhibit actin polymerization, the regulation imposed by RavJ  
371 is controlled by its metaeffector LegL1, which blocks its function by direct protein-protein  
372 interactions. LegL1 likely functions to spatially and temporally prevent RavJ from inducing  
373 excessive actin polymerization.



374

**S7 Fig. A predicted model of RavJ in actin cytoskeleton modulation.** RavJ catalyzes the crosslink between actin and AMOT, which led to the blockage of the ADF/cofilin binding site in actin, resulting in stabilization of actin fibers in the cell cortex.

375

376 Clathrin-vesicle associated proteins regulate vesicle assembly by binding directly  
377 to the actin filaments through a C-terminal talin-like domain, indicating important  
378 correlation between actin polymerization and endocytic vesicle trafficking[53]. Actin  
379 filaments also play a key role in maintaining ER structure and the ER-to-Golgi  
380 trafficking[54]. Given the extensive interconnection between vesicle trafficking and the  
381 actin cytoskeleton, RavJ is likely working in concert with VipA to enhance cargo  
382 transportation between ER and the LCV, thus facilitating fusions between the ER-derived  
383 vesicles and the LCV. Together, these effectors are likely work in concert to promote  
384 bacterial replication by indirectly interfering with the vesicle trafficking pathway.

385 **Materials and Methods**

386 **Media, bacteria strains, and cell lines.** *E. coli* strain DH5a was used for cloning and  
387 plasmid construction strains XL1-Blue and BL21(DE3) were used for expression and  
388 purification of all the recombinant proteins used in this study. *E. coli* strains were grown  
389 on LB agar plates or in LB broth. When necessary, antibiotics were added to media at the  
390 following concentrations: ampicillin, 100 µg/ml; kanamycin, 30 µg/ml. *L. pneumophila*  
391 strains used in this study were derivatives of the Philadelphia 1 strain Lp02[55]. Lp03 is  
392 an isogenic *dotA*<sup>-</sup> mutant of Lp02[56]. All strains were grown and maintained on CYE  
393 plates or in ACES-buffered yeast extract (AYE) broth as previously described[55]. For *L.*  
394 *pneumophila*, kanamycin was used at 30 µg/ml. When needed, thymidine was added at  
395 a final concentration of 100 µg/ml for thy autotrophic strains. The *ravJ* in-frame deletion  
396 strain was constructed by a two-step allelic exchange strategy as described  
397 previously[57]. HEK293T cells purchased from ATCC were cultured in Dulbecco's  
398 modified minimal Eagle's medium (DMEM) supplemented with 10% fetal bovine serum  
399 (FBS). Bone marrow-derived macrophages (BMDMs) were isolated and cultured as  
400 described previously[58]. All cell lines were regularly checked for potential mycoplasma  
401 contamination by the universal mycoplasma detection kit from ATCC (cat# 30-1012K).

402 **Plasmid constructions.** All the plasmids used in this study are listed in Table S1 and the  
403 bacterial strains and antibodies are in Table S2. For protein purifications, *ravJ*, *ravJ*<sub>C101A</sub>,  
404 and *legl1* were cloned into pQE30 (QIAGEN) or pGEX6p-1, respectively. For  
405 complementation experiments, *ravJ* and *ravJ*<sub>C101A</sub> were inserted into pZLQ-Flag, a  
406 derivative of pZLQ[59] that was modified to carry a Flag tag[60]. *legl1* was inserted into  
407 either pZLQ-Flag or pZL507[61] for overexpression in *L. pneumophila*. For ectopic

408 expression of proteins in mammalian cells, genes were inserted into the 4xFlag CMV [20],  
409 pFlag-CMV (Sigma), pEGFP-C1 (Clontech) vector, 3XHA pCDNA3.1 vector[62] or  
410 pAPH[63], a derivative of pVR1012 suitable for expressing proteins with an amino  
411 terminal HA tag. Human *AMOT* and *AMOTL1* were amplified from cDNAs of HEK293T  
412 cells and then inserted into BamHI/Sall of pAPH. For shRNA knockdown of *AMOTL1* in  
413 mammalian cells, pLKO.1-hygro vector (Addgene, plasmid #24150) was used to generate  
414 the pLKO.1-hygro-*AMOTL1*-sh construct. Packing plasmids psPAX2(Addgene, plasmid  
415 #12260) and pMD2.G (Addgene, plasmid #12259) were used for lentiviral constructs  
416 transduction.

417 **Transfection, immunoprecipitation, infection.** HEK293T cells grown to about 90%  
418 confluence were transfected with different plasmids, respectively, using Lipofectamine  
419 3000 (Thermo Fisher Scientific). Transfected cells were collected and lysed with  
420 radioimmunoprecipitation assay buffer (RIPA buffer, Thermo Fisher Scientific) at 18-24 h  
421 post transfection. When needed, immunoprecipitation was performed with lysates of  
422 transfected cells with Flag- or HA-specific antibody-coated agarose beads (Sigma-  
423 Aldrich, cat# F2426, Pierce, cat# 88836, respectively) at 4°C overnight. Beads were then  
424 washed with pre-cold RIPA buffer three times. For tandem purification, followed by RIPA  
425 wash, agarose beads with flag-tagged proteins were washed with Flag-to-His buffer (100  
426 mM Na-Phosphate, pH 8.0, 150 mM NaCl, 0.05% Triton X-100) three times and eluted  
427 with 3XFLAG peptide (Sigma-Aldrich, cat# F3290). Elution fraction was then subjected to  
428 HA beads, or Ni<sup>2+</sup>-NTA agarose beads (QIAGEN) as needed. Beads were resolved by  
429 SDS-PAGE gels followed by immunoblotting analysis with specific antibodies or silver  
430 staining following the manufacturer's protocols (Sigma-Aldrich, cat# PROTSIL1).

431 For infection experiments, *L. pneumophila* strains were grown to post-exponential  
432 phase (OD<sub>600</sub>=3.2-3.8) in AYE broth. Complementation strains and overexpression  
433 strains were induced with 0.5 mM IPTG for 2 h at 37°C before infection. HEK293T cells  
434 were transfected to express FcγII receptor[20]. *L. pneumophila* strains were incubated  
435 with *L. pneumophila*-specific anti-sera at a dilution of 1:500 for 30 minutes at 37°C. Cells  
436 were infected at an MOI of 50 for 4 h and then lysed with 0.2% saponin. Cell lysates were  
437 resolved by SDS-PAGE and followed by immunoblotting analysis with the specific  
438 antibodies.

439 **Antibodies and immunoblotting.** Purified His<sub>6</sub>-RavJ was used to raise rabbit specific  
440 antibodies following a standard protocol (Pocono Rabbit Farm & Laboratory). The  
441 antibodies were affinity-purified as described before[64]. For immunoblotting, samples  
442 resolved by SDS-PAGE were transferred onto 0.2 μm nitrocellulose membranes (Bio-  
443 Rad, cat# 1620112). Membranes were blocked with 5% non-fat milk, incubated with the  
444 appropriate primary antibodies: anti-HA (Sigma-Aldrich, cat# H3663), 1:5000; anti-tubulin  
445 (DSHB, E7), 1:10000, anti-Flag (Sigma-Aldrich, cat# F1804), 1:5000, anti-RavJ (this  
446 study), 1:5000, anti-Actin (MP Biomedicals, cat# 0869100), 1:5000, anti-AMOTL1  
447 (Sigma-Aldrich, cat# SAB1408393), 1:5000, anti-AMOT (Abnova, cat# H00154796-  
448 B01P), 1:5000, anti-ICDH[61], 1:10000, anti-GFP[61], 1:10000, anti-GST[61].  
449 Membranes were then incubated with an appropriate IRDye infrared secondary antibody  
450 and scanned by an Odyssey infrared imaging system (Li-Cor's Biosciences).

451 **Immunostaining.** HEK293T cells were seeded at 1X10<sup>5</sup> per well on glass coverslips in  
452 24-well plates. Cells were transfected to express the corresponding proteins for 24 h and  
453 were washed three times with PBS. Cells were fixed with 4% formaldehyde for 30 minutes

454 at room temperature, washed with PBS three times and were then permeabilized by 0.3%  
455 Triton at room temperature for 15 minutes. F-actin was stained with phalloidin conjugated  
456 with Texas-red (Thermo Fisher Scientific, cat#T7471) at a dilution of 1:500 for 1 h at room  
457 temperature. Images were acquired using an Olympus X-81 fluorescence microscope.

458 **Protein purification.** 10 ml overnight *E. coli* cultures were transferred to 400 ml LB  
459 medium supplemented with 100 µg/ml ampicillin or 30 µg/ml kanamycin and grown to  
460 OD<sub>600nm</sub> of 0.8-1.0. Cultures were then incubated at 18°C for 16-18 h after the addition of  
461 IPTG at a final concentration of 0.5 mM. Bacterial cells were spun down at 12,000 g and  
462 lysed by sonication. The soluble lysates were cleared by spinning at 12,000g twice at 4°C  
463 for 20 minutes. To purify His<sub>6</sub>-tagged proteins, supernatants were incubated with Ni<sup>2+</sup>-  
464 NTA beads for 2 h at 4°C followed by elution with 300 mM imidazole in TBS buffer after  
465 washing with 20X bed volumes of TBS buffer containing 20 mM imidazole. Purified  
466 proteins were dialyzed in buffer containing TBS, 5% glycerol and 1 mM DTT overnight at  
467 4°C. GST-tagged proteins were purified with glutathione beads (Pierce, cat# 16101) for  
468 2 h at 4°C followed by elution with elution buffer (50 Mm Tris pH 8.0, 0.4 M NaCl, 50 mM  
469 reduced glutathione, 0.1% Triton X-100, 1 mM DTT).

470 **shRNA knockdown of *AMOT* and *AMOTL1*.** MISSION shRNA retroviral constructs  
471 targeting *AMOT* was purchased from Sigma-Aldrich (Clone ID: NM\_133265.1-1628s1c1).  
472 To collect viral supernatant, cells were seeded at 2x10<sup>5</sup> cells/6 cm plate (around 10%  
473 confluence). After overnight culture, cells were transfected with the retroviral construct  
474 targeting *AMOT* along with two packing plasmids, psPAX2 and pMD2.G. The viral  
475 supernatant was collected at day 5 after transfection and was filtered with a 0.45-µm  
476 syringe filter. The titer of the produced lentivirus was determined by using Lenti-X Gostix

477 Plus Titer Kit (Takara, cat# 631281). To generate *AMOT* knockdown cell line, HEK293T  
478 cells were seeded at  $2 \times 10^5$  cells/10 cm plate (around 10% confluence). Media was  
479 removed at day 2 and viral supernatant was added to cover the whole plate (3.5 ml/10  
480 cm plate). Viral supernatant was added every 3 hours for three times. At day 3, media  
481 was replaced with fresh media. Cells were selected with media supplemented with  
482 puromycin (InvivoGen, cat# ant-pr-1) for a few days and single colonies were selected.

483 To generate *AMOTL1* knockdown cell line, the pLKO.1-hygro-*AMOTL1*-sh  
484 construct was generated by cloning annealed oligos 5'-  
485 CCGGTCCGGGCCCATCCTACAAACAACTTCTCGAGAAAGTT  
486 GTTTGTAGGATGGCTTTTG-3' and 5'-AATTCCAAAAAGGCCATCCTACAAAC  
487 AACTTCTCGAGAAAGTTGTTGATGGATGGGCCGGA-3' into the pLKO.1-hygro  
488 vector. Viral supernatant was generated by transfecting HEK293T cells with the retroviral  
489 construct targeting *AMOTL1* along with the packing plasmids, psPAX2 and pMD2.G. The  
490 viral supernatant was collected as described above. The *AMOT* knockdown cell line was  
491 infected with the viral supernatant as described above and single colonies were selected  
492 with media supplemented with hygromycin (Thermo Fisher Scientific, cat#10687010).

493 **Cell-free assays and *in vitro* assays.** In the cell-free assays, HEK293T cells expressing  
494 Flag-Actin, HA-AMOT, GFP-RavJ, GFP-RavJ<sub>C101A</sub>, HA-LegL1, respectively, were lysed  
495 by RIPA buffer without EDTA. Cell lysates were spun down at 12,000 g and the  
496 supernatants were collected. Reactions with combined supernatants as indicated were  
497 allowed to proceed for 2h at 37°C. the supernatants were then subjected to  
498 immunoprecipitation with Flag-antibody coated beads or HA-antibody coated beads as  
499 needed.

500 For *in vitro* assays, HEK293T cells expressing HA-AMOT, Flag-Actin respectively  
501 were lysed with RIPA buffer and then subjected to HA-IP or Flag-IP as needed. Proteins  
502 were eluted from the corresponding beads using 3XFLAG peptide or HA peptide (Thermo  
503 Fisher Scientific). 5 µg His<sub>6</sub>-RavJ or His<sub>6</sub>-RavJ<sub>C101A</sub> were added to the *in vitro* assay and  
504 the reaction was left in the 37°C incubator for 2 h. The in vitro reaction was then subjected  
505 to Flag-IP followed by SDS-PAGE analysis.

506 **Intracellular bacterial growth assay.** *L. pneumophila* strains were grown to the post-  
507 exponential phase (OD<sub>600</sub>=3.2-3.8) before infection. Bone marrow-derived mouse  
508 macrophages (BMDMs) isolated from female A/J mice as described before[58] were  
509 seeded onto 24-well plates and were infected with relevant *L. pneumophila* strains at an  
510 MOI of 0.05 at 37°C. Cells were collected at the indicated time points and lysed with  
511 0.02% saponin for half an hour on ice. The bacteria number was determined by  
512 enumerating colony-forming unit (CFU) of appropriately diluted saponin-soluble fractions.

513 **LC-MS/MS analysis.** Protein bands were digested in-gel with trypsin for protein  
514 identification. Peptides were re-suspended in 96.9% water, 3% acetonitrile (ACN), and  
515 0.1% formic acid (FA) at the final concentration of 0.2µg/µl, and 1 µg total peptides  
516 (equivalent volume) was analyzed by LC-ESI-MS/MS system using the Dionex UltiMate  
517 3000 RSLC nano System coupled to the Q Exactive™ HF Hybrid Quadrupole-Orbitrap  
518 Mass Spectrometer (Thermo Scientific, Waltham, MA) as described previously[65, 66].  
519 The reverse phase peptide separation was accomplished using a trap column (300 µm  
520 ID × 5 mm) packed with 5 µm 100 Å PepMap C18 medium, and then separated on a  
521 reverse phase column (50-cm long × 75 µm ID) packed with 2 µm 100 Å PepMap C18

522     silica (Thermo Fisher Scientific, Waltham, MA). The column temperature was maintained  
523     at 50 °C.

524           Mobile phase solvent A was 0.1% FA in water and solvent B was 0.1% FA in 80%  
525     ACN. Loading buffer was 98%water/2% ACN/0.1% FA. Peptides were separated by  
526     loading into the trap column in a loading buffer for 5-min at 5 µL/min flow rate and eluted  
527     from the analytical column at a flow rate of 150 nL/min using a 130-min LC gradient as  
528     follows: linear gradient of 5.1 to 27% of solvent B in 80 min, 27-45% in next 20 min, 45-  
529     100% of B in next 5 min at which point the gradient was held at 100% of B for 7 min before  
530     reverting back to 2% of B at 112 min, and hold at 2% of B for next 18 min for equilibration.  
531     The mass spectrometer was operated in positive ion and standard data-dependent  
532     acquisition mode with Advanced Peak Detection function activated for the top 20n. The  
533     fragmentation of precursor ion was accomplished by stepped normalized collision energy  
534     setting of 27%. The resolution of Orbitrap mass analyzer was set to 120,000 and 15,000  
535     for MS1 and MS2, respectively. The full scan MS1 spectra were collected in the mass  
536     range of 350-1,600 m/z, with an isolation window of 1.2m/z and a fixed first mass of 100  
537     m/z for MS2. The spray voltage was set at 2 and Automatic Gain Control (AGC) target of  
538     4e5 for MS1 and 5e4 for MS2, respectively.

539           For protein identification, the raw data were processed with the software  
540     MaxQuant[67] (version 1.6.3.3) against *Homo sapiens* database downloaded from the  
541     UniProt ([www.uniprot.org](http://www.uniprot.org)). The following parameters were edited for the searches:  
542     precursor mass tolerance of 10 ppm; enzyme specificity of trypsin enzyme allowing up to  
543     2 missed cleavages; oxidation of methionine (M) as a variable modification and  
544     carbamidomethylation of cysteine (C) as a fixed modification. False discovery rate (FDR)

545 of peptide spectral match (PSM) and protein identification was set to 0.01. The unique  
546 plus razor peptides (non-redundant, non-unique peptides assigned to the protein group  
547 with most other peptides) were used for peptide quantitation. LFQ intensity values were  
548 used for relative protein abundance measurement. Only proteins detected with at least  
549 one unique peptide and MS/MS  $\geq 2$  (spectral counts) were considered as true  
550 identification and used for downstream analysis.

551

552 **Materials Availability Statement:** All unique constructs and cell lines described in this  
553 article are available upon reasonable request from academic researchers. Please contact  
554 the corresponding author at [luoz@purdue.edu](mailto:luoz@purdue.edu) for request of any materials.

555

556 **Acknowledgements:** We thank Drs. Qing Deng, Matthew Olson and Chittaranjan Das  
557 (Purdue University) for helpful suggestions. We thank members of the Luo laboratory for  
558 helpful discussion. We also thank Dr. Uma K. Aryal from Purdue University and Dr.  
559 Jonathan Trinidad from the laboratory for Biological Mass Spectrometry at Indiana  
560 University for assistance in mass spectrometry analysis.

561

562 **References**

- 563 1. Vogel JP, Andrews HL, Wong SK, Isberg RR. Conjugative transfer by the virulence  
564 system of *Legionella pneumophila*. *Science*. 1998;279(5352):873-6. doi:  
565 10.1126/science.279.5352.873. PubMed PMID: 9452389.
- 566 2. Qiu J, Luo ZQ. *Legionella* and *Coxiella* effectors: strength in diversity and activity.  
567 *Nat Rev Microbiol*. 2017;15(10):591-605. Epub 20170717. doi: 10.1038/nrmicro.2017.67.  
568 PubMed PMID: 28713154.
- 569 3. Qiu J, Luo ZQ. Hijacking of the Host Ubiquitin Network by. *Front Cell Infect*  
570 *Microbiol*. 2017;7:487. Epub 20171205. doi: 10.3389/fcimb.2017.00487. PubMed PMID:  
571 29376029; PubMed Central PMCID: PMCPMC5770618.
- 572 4. Isberg RR, O'Connor TJ, Heidtman M. The *Legionella pneumophila* replication  
573 vacuole: making a cosy niche inside host cells. *Nat Rev Microbiol*. 2009;7(1):13-24. Epub  
574 20081117. doi: 10.1038/nrmicro1967. PubMed PMID: 19011659; PubMed Central  
575 PMCID: PMCPMC2631402.
- 576 5. Zhu W, Banga S, Tan Y, Zheng C, Stephenson R, Gately J, et al. Comprehensive  
577 identification of protein substrates of the Dot/Icm type IV transporter of *Legionella*  
578 *pneumophila*. *PLoS One*. 2011;6(3):e17638. Epub 20110309. doi:  
579 10.1371/journal.pone.0017638. PubMed PMID: 21408005; PubMed Central PMCID:  
580 PMCPMC3052360.
- 581 6. Huang L, Boyd D, Amyot WM, Hempstead AD, Luo ZQ, O'Connor TJ, et al. The E  
582 Block motif is associated with *Legionella pneumophila* translocated substrates. *Cell*  
583 *Microbiol*. 2011;13(2):227-45. Epub 20101103. doi: 10.1111/j.1462-5822.2010.01531.x.  
584 PubMed PMID: 20880356; PubMed Central PMCID: PMCPMC3096851.
- 585 7. Pollard TD, Cooper JA. Actin, a central player in cell shape and movement.  
586 *Science*. 2009;326(5957):1208-12. doi: 10.1126/science.1175862. PubMed PMID:  
587 19965462; PubMed Central PMCID: PMCPMC3677050.
- 588 8. Richard JF, Petit L, Gibert M, Marvaud JC, Bouchaud C, Popoff MR. Bacterial  
589 toxins modifying the actin cytoskeleton. *Int Microbiol*. 1999;2(3):185-94. PubMed PMID:  
590 10943412.
- 591 9. Ono S. A plague of actin disassembly. *J Biol Chem*. 2017;292(19):8101-2. doi:  
592 10.1074/jbc.H116.757971. PubMed PMID: 28500241; PubMed Central PMCID:  
593 PMCPMC5427285.
- 594 10. Galan JE, Zhou D. Striking a balance: modulation of the actin cytoskeleton by  
595 *Salmonella*. *Proc Natl Acad Sci U S A*. 2000;97(16):8754-61. doi:  
596 10.1073/pnas.97.16.8754. PubMed PMID: 10922031; PubMed Central PMCID:  
597 PMCPMC34008.
- 598 11. Liu Y, Zhu W, Tan Y, Nakayasu ES, Staiger CJ, Luo ZQ. A *Legionella* Effector  
599 Disrupts Host Cytoskeletal Structure by Cleaving Actin. *PLoS Pathog*.  
600 2017;13(1):e1006186. Epub 20170127. doi: 10.1371/journal.ppat.1006186. PubMed  
601 PMID: 28129393; PubMed Central PMCID: PMCPMC5298343.
- 602 12. Michard C, Sperandio D, Baïlo N, Pizarro-Cerdá J, LeClaire L, Chadeau-Argaud  
603 E, et al. The *Legionella* Kinase LegK2 Targets the ARP2/3 Complex To Inhibit Actin  
604 Nucleation on Phagosomes and Allow Bacterial Evasion of the Late Endocytic Pathway.  
605 *mBio*. 2015;6(3):e00354-15. Epub 20150505. doi: 10.1128/mBio.00354-15. PubMed  
606 PMID: 25944859; PubMed Central PMCID: PMCPMC4436068.

- 607 13. Guo Z, Stephenson R, Qiu J, Zheng S, Luo ZQ. A *Legionella* effector modulates  
608 host cytoskeletal structure by inhibiting actin polymerization. *Microbes Infect.*  
609 2014;16(3):225-36. Epub 20131126. doi: 10.1016/j.micinf.2013.11.007. PubMed PMID:  
610 24286927; PubMed Central PMCID: PMCPMC3965633.
- 611 14. Franco IS, Shohdy N, Shuman HA. The *Legionella pneumophila* effector VipA is  
612 an actin nucleator that alters host cell organelle trafficking. *PLoS Pathog.*  
613 2012;8(2):e1002546. Epub 20120223. doi: 10.1371/journal.ppat.1002546. PubMed  
614 PMID: 22383880; PubMed Central PMCID: PMCPMC3285593.
- 615 15. Chambers KA, Scheck RA. Bacterial virulence mediated by orthogonal post-  
616 translational modification. *Nat Chem Biol.* 2020;16(10):1043-51. Epub 20200917. doi:  
617 10.1038/s41589-020-0638-2. PubMed PMID: 32943788.
- 618 16. Mukherjee S, Liu X, Arasaki K, McDonough J, Galán JE, Roy CR. Modulation of  
619 Rab GTPase function by a protein phosphocholine transferase. *Nature.*  
620 2011;477(7362):103-6. Epub 20110807. doi: 10.1038/nature10335. PubMed PMID:  
621 21822290; PubMed Central PMCID: PMCPMC3206611.
- 622 17. Tan Y, Arnold RJ, Luo ZQ. *Legionella pneumophila* regulates the small GTPase  
623 Rab1 activity by reversible phosphorylcholination. *Proc Natl Acad Sci U S A.*  
624 2011;108(52):21212-7. Epub 20111207. doi: 10.1073/pnas.1114023109. PubMed PMID:  
625 22158903; PubMed Central PMCID: PMCPMC3248503.
- 626 18. Müller MP, Peters H, Blümer J, Blankenfeldt W, Goody RS, Itzen A. The *Legionella*  
627 effector protein DrrA AMPylates the membrane traffic regulator Rab1b. *Science.*  
628 2010;329(5994):946-9. Epub 20100722. doi: 10.1126/science.1192276. PubMed PMID:  
629 20651120.
- 630 19. Lee PC, Machner MP. The *Legionella* Effector Kinase LegK7 Hijacks the Host  
631 Hippo Pathway to Promote Infection. *Cell Host Microbe.* 2018;24(3):429-38.e6. doi:  
632 10.1016/j.chom.2018.08.004. PubMed PMID: 30212651; PubMed Central PMCID:  
633 PMCPMC7343393.
- 634 20. Qiu J, Sheedlo MJ, Yu K, Tan Y, Nakayasu ES, Das C, et al. Ubiquitination  
635 independent of E1 and E2 enzymes by bacterial effectors. *Nature.* 2016;533(7601):120-  
636 4. Epub 20160406. doi: 10.1038/nature17657. PubMed PMID: 27049943; PubMed  
637 Central PMCID: PMCPMC4905768.
- 638 21. Black MH, Osinski A, Park GJ, Gradowski M, Servage KA, Pawłowski K, et al. A  
639 *Legionella* effector ADP-ribosyltransferase inactivates glutamate dehydrogenase. *J Biol*  
640 *Chem.* 2021;296:100301. Epub 20210118. doi: 10.1016/j.jbc.2021.100301. PubMed  
641 PMID: 33476647; PubMed Central PMCID: PMCPMC7949102.
- 642 22. Fu J, Zhou M, Gritsenko MA, Nakayasu ES, Song L, Luo ZQ. modulates host  
643 energy metabolism by ADP-ribosylation of ADP/ATP translocases. *Elife.* 2022;11. Epub  
644 20220127. doi: 10.7554/elife.73611. PubMed PMID: 35084332; PubMed Central  
645 PMCID: PMCPMC8820735.
- 646 23. Gan N, Nakayasu ES, Hollenbeck PJ, Luo ZQ. *Legionella pneumophila* inhibits  
647 immune signalling via MavC-mediated transglutaminase-induced ubiquitination of  
648 UBE2N. *Nat Microbiol.* 2019;4(1):134-43. Epub 20181112. doi: 10.1038/s41564-018-  
649 0282-8. PubMed PMID: 30420781; PubMed Central PMCID: PMCPMC6294664.
- 650 24. Lorand L, Graham RM. Transglutaminases: crosslinking enzymes with pleiotropic  
651 functions. *Nat Rev Mol Cell Biol.* 2003;4(2):140-56. doi: 10.1038/nrm1014. PubMed  
652 PMID: 12563291.

- 653 25. Nimchuk ZL, Fisher EJ, Desveaux D, Chang JH, Dangl JL. The HopX (AvrPphE)  
654 family of *Pseudomonas syringae* type III effectors require a catalytic triad and a novel N-  
655 terminal domain for function. *Mol Plant Microbe Interact.* 2007;20(4):346-57. doi:  
656 10.1094/MPMI-20-4-0346. PubMed PMID: 17427805.
- 657 26. Zhang L, Krachler AM, Broberg CA, Li Y, Mirzaei H, Gilpin CJ, et al. Type III  
658 effector VopC mediates invasion for *Vibrio* species. *Cell Rep.* 2012;1(5):453-60. Epub  
659 20120503. doi: 10.1016/j.celrep.2012.04.004. PubMed PMID: 22787576; PubMed  
660 Central PMCID: PMCPMC3392014.
- 661 27. Urbanus ML, Quaile AT, Stogios PJ, Morar M, Rao C, Di Leo R, et al. Diverse  
662 mechanisms of metaeffector activity in an intracellular bacterial pathogen, *Legionella*  
663 *pneumophila*. *Mol Syst Biol.* 2016;12(12):893. Epub 20161216. doi:  
664 10.15252/msb.20167381. PubMed PMID: 27986836; PubMed Central PMCID:  
665 PMCPMC5199130.
- 666 28. Huang T, Zhou Y, Zhang J, Cheng ASL, Yu J, To KF, et al. The physiological role  
667 of Motin family and its dysregulation in tumorigenesis. *J Transl Med.* 2018;16(1):98. Epub  
668 20180412. doi: 10.1186/s12967-018-1466-y. PubMed PMID: 29650031; PubMed Central  
669 PMCID: PMCPMC5898069.
- 670 29. Bratt A, Wilson WJ, Troyanovsky B, Aase K, Kessler R, Van Meir EG, et al.  
671 Angiomotin belongs to a novel protein family with conserved coiled-coil and PDZ binding  
672 domains. *Gene.* 2002;298(1):69-77. doi: 10.1016/s0378-1119(02)00928-9. PubMed  
673 PMID: 12406577.
- 674 30. Zhao B, Li L, Lu Q, Wang LH, Liu CY, Lei Q, et al. Angiomotin is a novel Hippo  
675 pathway component that inhibits YAP oncoprotein. *Genes Dev.* 2011;25(1):51-63. doi:  
676 10.1101/gad.2000111. PubMed PMID: 21205866; PubMed Central PMCID:  
677 PMCPMC3012936.
- 678 31. McGough A, Pope B, Chiu W, Weeds A. Cofilin changes the twist of F-actin:  
679 implications for actin filament dynamics and cellular function. *J Cell Biol.* 1997;138(4):771-  
680 81. doi: 10.1083/jcb.138.4.771. PubMed PMID: 9265645; PubMed Central PMCID:  
681 PMCPMC2138052.
- 682 32. Schutt CE, Myslik JC, Rozycki MD, Goonesekere NC, Lindberg U. The structure  
683 of crystalline profilin-beta-actin. *Nature.* 1993;365(6449):810-6. doi: 10.1038/365810a0.  
684 PubMed PMID: 8413665.
- 685 33. Ezezika OC, Younger NS, Lu J, Kaiser DA, Corbin ZA, Nolen BJ, et al.  
686 Incompatibility with formin Cdc12p prevents human profilin from substituting for fission  
687 yeast profilin: insights from crystal structures of fission yeast profilin. *J Biol Chem.*  
688 2009;284(4):2088-97. Epub 20081120. doi: 10.1074/jbc.M807073200. PubMed PMID:  
689 19028693; PubMed Central PMCID: PMCPMC2629104.
- 690 34. Pfaendtner J, De La Cruz EM, Voth GA. Actin filament remodeling by actin  
691 depolymerization factor/cofilin. *Proc Natl Acad Sci U S A.* 2010;107(16):7299-304. Epub  
692 20100405. doi: 10.1073/pnas.0911675107. PubMed PMID: 20368459; PubMed Central  
693 PMCID: PMCPMC2867716.
- 694 35. Revenu C, Athman R, Robine S, Louvard D. The co-workers of actin filaments:  
695 from cell structures to signals. *Nat Rev Mol Cell Biol.* 2004;5(8):635-46. doi:  
696 10.1038/nrm1437. PubMed PMID: 15366707.
- 697 36. Colonne PM, Winchell CG, Voth DE. Hijacking Host Cell Highways: Manipulation  
698 of the Host Actin Cytoskeleton by Obligate Intracellular Bacterial Pathogens. *Front Cell*

- 699 Infect Microbiol. 2016;6:107. Epub 20160922. doi: 10.3389/fcimb.2016.00107. PubMed  
700 PMID: 27713866; PubMed Central PMCID: PMCPMC5031698.
- 701 37. Meconi S, Jacomo V, Boquet P, Raoult D, Mege JL, Capo C. *Coxiella burnetii*  
702 induces reorganization of the actin cytoskeleton in human monocytes. Infect Immun.  
703 1998;66(11):5527-33. doi: 10.1128/IAI.66.11.5527-5533.1998. PubMed PMID: 9784567;  
704 PubMed Central PMCID: PMCPMC108693.
- 705 38. Aguilera M, Salinas R, Rosales E, Carminati S, Colombo MI, Berón W. Actin  
706 dynamics and Rho GTPases regulate the size and formation of parasitophorous vacuoles  
707 containing *Coxiella burnetii*. Infect Immun. 2009;77(10):4609-20. Epub 20090727. doi:  
708 10.1128/IAI.00301-09. PubMed PMID: 19635823; PubMed Central PMCID:  
709 PMCPMC2747940.
- 710 39. Campbell S, Richmond SJ, Yates PS. The effect of *Chlamydia trachomatis*  
711 infection on the host cell cytoskeleton and membrane compartments. J Gen Microbiol.  
712 1989;135(9):2379-86. doi: 10.1099/00221287-135-9-2379. PubMed PMID: 2483409.
- 713 40. Kumar Y, Valdivia RH. Actin and intermediate filaments stabilize the *Chlamydia*  
714 *trachomatis* vacuole by forming dynamic structural scaffolds. Cell Host Microbe.  
715 2008;4(2):159-69. doi: 10.1016/j.chom.2008.05.018. PubMed PMID: 18692775; PubMed  
716 Central PMCID: PMCPMC2605408.
- 717 41. Gouin E, Egile C, Dehoux P, Villiers V, Adams J, Gertler F, et al. The RickA protein  
718 of *Rickettsia conorii* activates the Arp2/3 complex. Nature. 2004;427(6973):457-61. doi:  
719 10.1038/nature02318. PubMed PMID: 14749835.
- 720 42. Jeng RL, Goley ED, D'Alessio JA, Chaga OY, Svitkina TM, Borisy GG, et al. A  
721 *Rickettsia* WASP-like protein activates the Arp2/3 complex and mediates actin-based  
722 motility. Cell Microbiol. 2004;6(8):761-9. doi: 10.1111/j.1462-5822.2004.00402.x.  
723 PubMed PMID: 15236643.
- 724 43. Oda T, Iwasa M, Aihara T, Maéda Y, Narita A. The nature of the globular- to  
725 fibrous-actin transition. Nature. 2009;457(7228):441-5. doi: 10.1038/nature07685.  
726 PubMed PMID: 19158791.
- 727 44. Martinez-Quiles N, Rohatgi R, Antón IM, Medina M, Saville SP, Miki H, et al. WIP  
728 regulates N-WASP-mediated actin polymerization and filopodium formation. Nat Cell Biol.  
729 2001;3(5):484-91. doi: 10.1038/35074551. PubMed PMID: 11331876.
- 730 45. Kühn S, Mannherz HG. Actin: Structure, Function, Dynamics, and Interactions with  
731 Bacterial Toxins. Curr Top Microbiol Immunol. 2017;399:1-34. doi: 10.1007/82\_2016\_45.  
732 PubMed PMID: 27848038.
- 733 46. Horwitz MA. The Legionnaires' disease bacterium (*Legionella pneumophila*)  
734 inhibits phagosome-lysosome fusion in human monocytes. J Exp Med.  
735 1983;158(6):2108-26. doi: 10.1084/jem.158.6.2108. PubMed PMID: 6644240; PubMed  
736 Central PMCID: PMCPMC2187157.
- 737 47. Derré I, Isberg RR. *Legionella pneumophila* replication vacuole formation involves  
738 rapid recruitment of proteins of the early secretory system. Infect Immun.  
739 2004;72(5):3048-53. doi: 10.1128/IAI.72.5.3048-3053.2004. PubMed PMID: 15102819;  
740 PubMed Central PMCID: PMCPMC387905.
- 741 48. Swanson MS, Isberg RR. Association of *Legionella pneumophila* with the  
742 macrophage endoplasmic reticulum. Infect Immun. 1995;63(9):3609-20. doi:  
743 10.1128/iai.63.9.3609-3620.1995. PubMed PMID: 7642298; PubMed Central PMCID:  
744 PMCPMC173501.

- 745 49. Kagan JC, Roy CR. Legionella phagosomes intercept vesicular traffic from  
746 endoplasmic reticulum exit sites. *Nat Cell Biol.* 2002;4(12):945-54. doi: 10.1038/ncb883.  
747 PubMed PMID: 12447391.
- 748 50. Shin S, Roy CR. Host cell processes that influence the intracellular survival of  
749 Legionella pneumophila. *Cell Microbiol.* 2008;10(6):1209-20. Epub 20080317. doi:  
750 10.1111/j.1462-5822.2008.01145.x. PubMed PMID: 18363881.
- 751 51. Heidman M, Chen EJ, Moy MY, Isberg RR. Large-scale identification of Legionella  
752 pneumophila Dot/Icm substrates that modulate host cell vesicle trafficking pathways. *Cell*  
753 *Microbiol.* 2009;11(2):230-48. Epub 20081030. doi: 10.1111/j.1462-5822.2008.01249.x.  
754 PubMed PMID: 19016775; PubMed Central PMCID: PMCPMC2744955.
- 755 52. Iyer S, Das C. The unity of opposites: Strategic interplay between bacterial  
756 effectors to regulate cellular homeostasis. *J Biol Chem.* 2021;297(6):101340. Epub  
757 20211023. doi: 10.1016/j.jbc.2021.101340. PubMed PMID: 34695417; PubMed Central  
758 PMCID: PMCPMC8605245.
- 759 53. Hehnly H, Starnes M. Regulating cytoskeleton-based vesicle motility. *FEBS Lett.*  
760 2007;581(11):2112-8. Epub 20070220. doi: 10.1016/j.febslet.2007.01.094. PubMed  
761 PMID: 17335816; PubMed Central PMCID: PMCPMC1974873.
- 762 54. Kee AJ, Bryce NS, Yang L, Polishchuk E, Schevzov G, Weigert R, et al. ER/Golgi  
763 trafficking is facilitated by unbranched actin filaments containing Tpm4.2. *Cytoskeleton*  
764 (Hoboken). 2017;74(10):379-89. Epub 20170831. doi: 10.1002/cm.21405. PubMed  
765 PMID: 28834398; PubMed Central PMCID: PMCPMC7971414.
- 766 55. Berger KH, Isberg RR. Two distinct defects in intracellular growth complemented  
767 by a single genetic locus in *Legionella pneumophila*. *Mol Microbiol.* 1993;7(1):7-19. doi:  
768 10.1111/j.1365-2958.1993.tb01092.x. PubMed PMID: 8382332.
- 769 56. Berger KH, Merriam JJ, Isberg RR. Altered intracellular targeting properties  
770 associated with mutations in the *Legionella pneumophila* dotA gene. *Mol Microbiol.*  
771 1994;14(4):809-22. doi: 10.1111/j.1365-2958.1994.tb01317.x. PubMed PMID: 7891566.
- 772 57. Luo ZQ, Isberg RR. Multiple substrates of the *Legionella pneumophila* Dot/Icm  
773 system identified by interbacterial protein transfer. *Proc Natl Acad Sci U S A.*  
774 2004;101(3):841-6. Epub 20040108. doi: 10.1073/pnas.0304916101. PubMed PMID:  
775 14715899; PubMed Central PMCID: PMCPMC321768.
- 776 58. Conover GM, Derré I, Vogel JP, Isberg RR. The *Legionella pneumophila* LidA  
777 protein: a translocated substrate of the Dot/Icm system associated with maintenance of  
778 bacterial integrity. *Mol Microbiol.* 2003;48(2):305-21. doi: 10.1046/j.1365-  
779 2958.2003.03400.x. PubMed PMID: 12675793.
- 780 59. Luo ZQ, Farrand SK. Signal-dependent DNA binding and functional domains of  
781 the quorum-sensing activator TraR as identified by repressor activity. *Proc Natl Acad Sci*  
782 *U S A.* 1999;96(16):9009-14. doi: 10.1073/pnas.96.16.9009. PubMed PMID: 10430886;  
783 PubMed Central PMCID: PMCPMC17723.
- 784 60. McCloskey A, Perri K, Chen T, Han A, Luo ZQ. The metaeffector MesI regulates  
785 the activity of the *Legionella* effector SidI through direct protein-protein interactions.  
786 *Microbes Infect.* 2021;23(4-5):104794. Epub 20210208. doi:  
787 10.1016/j.micinf.2021.104794. PubMed PMID: 33571674; PubMed Central PMCID:  
788 PMCPMC9406241.
- 789 61. Xu L, Shen X, Bryan A, Banga S, Swanson MS, Luo ZQ. Inhibition of host vacuolar  
790 H<sup>+</sup>-ATPase activity by a *Legionella pneumophila* effector. *PLoS Pathog.*

- 791 2010;6(3):e1000822. Epub 20100319. doi: 10.1371/journal.ppat.1000822. PubMed  
792 PMID: 20333253; PubMed Central PMCID: PMCPMC2841630.
- 793 62. Sheedlo MJ, Qiu J, Tan Y, Paul LN, Luo ZQ, Das C. Structural basis of substrate  
794 recognition by a bacterial deubiquitinase important for dynamics of phagosome  
795 ubiquitination. *Proc Natl Acad Sci U S A.* 2015;112(49):15090-5. Epub 20151123. doi:  
796 10.1073/pnas.1514568112. PubMed PMID: 26598703; PubMed Central PMCID:  
797 PMCPMC4679006.
- 798 63. Wang SH, Wang A, Liu PP, Zhang WY, Du J, Xu S, et al. Divergent Pathogenic  
799 Properties of Circulating Coxsackievirus A6 Associated with Emerging Hand, Foot, and  
800 Mouth Disease. *J Virol.* 2018;92(11). Epub 20180514. doi: 10.1128/JVI.00303-18.  
801 PubMed PMID: 29563294; PubMed Central PMCID: PMCPMC5952127.
- 802 64. Hubber A, Arasaki K, Nakatsu F, Hardiman C, Lambright D, De Camilli P, et al.  
803 The machinery at endoplasmic reticulum-plasma membrane contact sites contributes to  
804 spatial regulation of multiple *Legionella* effector proteins. *PLoS Pathog.*  
805 2014;10(7):e1004222. Epub 20140703. doi: 10.1371/journal.ppat.1004222. PubMed  
806 PMID: 24992562; PubMed Central PMCID: PMCPMC4081824.
- 807 65. Connelly KE, Hedrick V, Paschoal Sobreira TJ, Dykhuizen EC, Aryal UK. Analysis  
808 of Human Nuclear Protein Complexes by Quantitative Mass Spectrometry Profiling.  
809 *Proteomics.* 2018;18(11):e1700427. Epub 20180504. doi: 10.1002/pmic.201700427.  
810 PubMed PMID: 29655301; PubMed Central PMCID: PMCPMC6387628.
- 811 66. Mohallem R, Aryal UK. Regulators of TNF $\alpha$  mediated insulin resistance elucidated  
812 by quantitative proteomics. *Sci Rep.* 2020;10(1):20878. Epub 20201130. doi:  
813 10.1038/s41598-020-77914-1. PubMed PMID: 33257747; PubMed Central PMCID:  
814 PMCPMC7705713.
- 815 67. Cox J, Mann M. MaxQuant enables high peptide identification rates, individualized  
816 p.p.b.-range mass accuracies and proteome-wide protein quantification. *Nat Biotechnol.*  
817 2008;26(12):1367-72. Epub 20081130. doi: 10.1038/nbt.1511. PubMed PMID:  
818 19029910.